STAT Plus: What Sarepta’s game-changing data mean for biotech’s other Duchenne players

Sarepta is the toast of biotech after revealing early data on a gene therapy for Duchenne muscular dystrophy. Here's what the data mean for competitors.

More From BioPortfolio on "STAT Plus: What Sarepta’s game-changing data mean for biotech’s other Duchenne players"